Quoin pharmaceuticals and genpharm services sign exclusive license and distribution agreement for quoin's lead asset, qrx003

Ashburn, va., nov. 11, 2021 (globe newswire) -- quoin pharmaceuticals ltd. (nasdaq: qnrx) (the “company” or “quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, and genpharm services, a regional rare disease and specialty pharmaceutical company, today announced that they have entered into an exclusive license and distribution agreement for qrx003, quoin's investigational treatment for netherton syndrome, a rare and devastating genetic disease.
QNRX Ratings Summary
QNRX Quant Ranking